Portal:AOP/FeaturedPathways
From WikiPathways
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | *[[Pathway:WP3997]] | + | *[[Pathway:WP3997]] Epilepsy Adverse Outcome Pathway (Homo sapiens) |
| - | *[[Pathway:WP3980]] | + | *[[Pathway:WP3980]] Protein alkylation leading to liver fibrosis (Homo sapiens) |
*[[Pathway:WP3624]] Lung fibrosis (Homo sapiens) | *[[Pathway:WP3624]] Lung fibrosis (Homo sapiens) | ||
| - | *[[Pathway:WP3632]] | + | *[[Pathway:WP3632]] Lung fibrosis (Mus musculus) |
| - | *[[Pathway:WP4010]] | + | *[[Pathway:WP4010]] Liver steatosis AOP (Homo sapiens) |
| - | *[[Pathway:WP4011]] | + | *[[Pathway:WP4011]] Steatosis AOP (Homo sapiens) |
| - | *[[Pathway:WP4017]] | + | *[[Pathway:WP4017]] Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens) |
| - | *[[Pathway:WP4026]] | + | *[[Pathway:WP4026]] Gastric ulcer formation (Homo sapiens) |
Revision as of 10:36, 23 March 2018
- Pathway:WP3997 Epilepsy Adverse Outcome Pathway (Homo sapiens)
- Pathway:WP3980 Protein alkylation leading to liver fibrosis (Homo sapiens)
- Pathway:WP3624 Lung fibrosis (Homo sapiens)
- Pathway:WP3632 Lung fibrosis (Mus musculus)
- Pathway:WP4010 Liver steatosis AOP (Homo sapiens)
- Pathway:WP4011 Steatosis AOP (Homo sapiens)
- Pathway:WP4017 Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens)
- Pathway:WP4026 Gastric ulcer formation (Homo sapiens)
